Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
Recruiting now
Conditions studied: Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin
In brief
This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.
Key facts
- Study ID
- NCT03117036
- Run by
- Samsung Medical Center
- People needed
- 600
- Starts
- 2017-03-01
- Expected to finish
- 2026-12-28
- Last updated by the study team
- 2025-05-21
Who can join
Age: 20 and older, up to 90. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
- 20 years
- Patients requiring systemic chemotherapy with curative intent
- Written informed consent
You may not qualify if…
- Myeloid malignancy
- Multiple myeloma
- Patients do not require systemic chemotherapy with curative intent
Where it is running
- Samsung Medical Center — Seoul, South Korea (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.